Shire PLC Company Profile (NASDAQ:SHPG)


Shire PLC logoShire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:SHPG
  • CUSIP: N/A
  • Web:
Average Prices:
  • 50 Day Moving Avg: $166.71
  • 200 Day Moving Avg: $173.47
  • 52 Week Range: $158.54 - $209.22
  • Trailing P/E Ratio: 167.84
  • Foreward P/E Ratio: 10.05
  • P/E Growth: 0.83
  • Annual Dividend: $0.91
  • Dividend Yield: 0.6%
  • Net Margins: 2.14%
  • Return on Equity: 13.05%
  • Return on Assets: 5.64%
  • Debt-to-Equity Ratio: 0.66%
  • Current Ratio: 1.01%
  • Quick Ratio: 0.54%
  • Beta: 1.6
Frequently Asked Questions for Shire PLC (NASDAQ:SHPG)

What is Shire PLC's stock symbol?

Shire PLC trades on the NASDAQ under the ticker symbol "SHPG."

How often does Shire PLC pay dividends? What is the dividend yield for Shire PLC?

Shire PLC announced a dividend on Friday, February 24th. Shareholders of record on Friday, March 10th will be paid a dividend of $0.771 per share on Tuesday, April 25th. The ex-dividend date of this dividend is Wednesday, March 8th. This is a boost from Shire PLC's previous dividend of $0.14. View Shire PLC's Dividend History.

How were Shire PLC's earnings last quarter?

Shire PLC (NASDAQ:SHPG) issued its quarterly earnings data on Tuesday, May, 2nd. The company reported $3.63 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $3.22 by $0.41. The business had revenue of $3.57 billion for the quarter. Shire PLC had a net margin of 2.14% and a return on equity of 13.05%. The business's revenue was up 109.0% compared to the same quarter last year. During the same period in the previous year, the business posted $2.12 earnings per share. View Shire PLC's Earnings History.

What guidance has Shire PLC issued on next quarter's earnings?

Shire PLC issued an update on its FY17 earnings guidance on Tuesday, May, 2nd. The company provided earnings per share guidance of $14.60-15.20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $15.00. The company issued revenue guidance of $14.5-14.8 billion, compared to the consensus revenue estimate of $15.23 billion.

Where is Shire PLC's stock going? Where will Shire PLC's stock price be in 2017?

20 equities research analysts have issued 12-month price objectives for Shire PLC's stock. Their predictions range from $198.00 to $325.00. On average, they anticipate Shire PLC's share price to reach $229.10 in the next year. View Analyst Ratings for Shire PLC.

What are analysts saying about Shire PLC stock?

Here are some recent quotes from research analysts about Shire PLC stock:

  • 1. According to Zacks Investment Research, "The approval of Mydayis is likely to boost Shire’s ADHD segment dominance while strong performance of Vyvanse, Cinryze and Elaprase will continue to drive Shire’s top line. The label expansion of Cinryze in paediatrics and conditional approval of Natpara in Europe should continue to drive the top line going ahead. The hematology and immunology segment, acquired from Baxalta, gave a major boost to product sales. The approval of Xiidra has boosted the company’s ophthalmology space, acquiring roughly 22% of the total market by the end of Mar 2017. The Dyax acquisition has integrated well and Shire announced positive results from the phase III trial on lanadelumab in May 2017. However, the adult ADHD space is one of the largest and fastest growing segments of the market but is highly genericized. Earnings estimates have fallen lately ahead of the Q2 results. Shire has a positive record of earnings surprises in the recent quarters." (7/17/2017)
  • 2. Jefferies Group LLC analysts commented, "SHPG posted strong 4Q16 revs ($3.8B vs $3.7B JEF) and EPS ($3.37 vs $3.26 JEF) as nearly all core franchises performed well. In particular, GI and Orphan Diseases showed strength. As for legacy BXLT, Immunoglobulins and Hemophilia performed well while Inhibitors lagged. We like the setup for 2017. If mgt executes on core brands, the Xiidra launch, and the BXLT integration, we could envision share price outperformance, augmented by significant deleveraging." (2/17/2017)

Are investors shorting Shire PLC?

Shire PLC saw a increase in short interest in the month of July. As of July 14th, there was short interest totalling 1,247,044 shares, an increase of 34.9% from the June 30th total of 924,373 shares. Based on an average trading volume of 1,330,164 shares, the days-to-cover ratio is currently 0.9 days.

Who are some of Shire PLC's key competitors?

Who are Shire PLC's key executives?

Shire PLC's management team includes the folowing people:

  • Flemming Ornskov M.D., Chief Executive Officer, Executive Director
  • Jeffrey Poulton, Chief Financial Officer, Executive Director
  • William Mordan, General Counsel, Company Secretary
  • Perry Sternberg, Head - U.S. Commercial
  • Kim Stratton, Head - International Commercial
  • Philip J. Vickers, Head - Research and Development
  • Matthew Walker, Head - Technical Operations
  • Susan Saltzbart Kilsby, Independent Non-Executive Chairman of the Board
  • Olivier Bohuon, Non-Executive Director
  • Ian T. Clark, Non-Executive Director

Who owns Shire PLC stock?

Shire PLC's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Rockefeller Financial Services Inc. (0.00%), Selz Capital LLC (0.03%), Aperio Group LLC (0.00%), Fisher Asset Management LLC (0.00%), Gateway Investment Advisers LLC (0.00%) and US Bancorp DE (0.00%). View Institutional Ownership Trends for Shire PLC.

Who sold Shire PLC stock? Who is selling Shire PLC stock?

Shire PLC's stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Rockefeller Financial Services Inc., Quantitative Systematic Strategies LLC, Bank of Montreal Can, Catawba Capital Management VA, Leavell Investment Management Inc., Private Trust Co. NA and Fox Run Management L.L.C.. View Insider Buying and Selling for Shire PLC.

Who bought Shire PLC stock? Who is buying Shire PLC stock?

Shire PLC's stock was purchased by a variety of institutional investors in the last quarter, including Selz Capital LLC, Gateway Investment Advisers LLC, Osborne Partners Capital Management LLC, US Bancorp DE, Heritage Investors Management Corp, Breton Hill Capital Ltd., Altfest L J & Co. Inc. and Addison Capital Co. View Insider Buying and Selling for Shire PLC.

How do I buy Shire PLC stock?

Shares of Shire PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Shire PLC's stock price today?

One share of Shire PLC stock can currently be purchased for approximately $166.11.

MarketBeat Community Rating for Shire PLC (NASDAQ SHPG)
Community Ranking:  3.6 out of 5 (  )
Outperform Votes:  770 (Vote Outperform)
Underperform Votes:  302 (Vote Underperform)
Total Votes:  1,072
MarketBeat's community ratings are surveys of what our community members think about Shire PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Shire PLC (NASDAQ:SHPG) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Hold Ratings, 15 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $229.10 (37.92% upside)

Analysts' Ratings History for Shire PLC (NASDAQ:SHPG)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/17/2017BTIG ResearchReiterated RatingBuy$242.00LowView Rating Details
7/13/2017Sanford C. BernsteinReiterated RatingMarket Perform$210.00LowView Rating Details
7/12/2017Stifel NicolausReiterated RatingBuy$245.00LowView Rating Details
7/11/2017Cantor FitzgeraldSet Price TargetBuy$222.00MediumView Rating Details
7/6/2017HSBC Holdings plcUpgradeReduce -> HoldMediumView Rating Details
6/9/2017Jefferies Group LLCReiterated RatingBuy -> Buy$239.00 -> $216.00LowView Rating Details
6/8/2017Royal Bank Of CanadaSet Price TargetBuy$218.00LowView Rating Details
6/1/2017Liberum CapitalDowngradeBuy -> HoldLowView Rating Details
5/31/2017Cowen and CompanyReiterated RatingOutperform$325.00LowView Rating Details
4/17/2017Goldman Sachs Group, Inc. (The)Boost Price TargetOverweight$202.00 -> $214.00LowView Rating Details
3/7/2017Barclays PLCInitiated CoverageOverweightN/AView Rating Details
2/17/2017GuggenheimReiterated RatingNeutralN/AView Rating Details
12/2/2016Societe GeneraleInitiated CoverageBuyN/AView Rating Details
11/14/2016Leerink SwannSet Price TargetBuy$198.00N/AView Rating Details
11/7/2016J P Morgan Chase & CoReiterated RatingOverweightN/AView Rating Details
11/3/2016Citigroup Inc.Reiterated RatingBuyN/AView Rating Details
11/2/2016Deutsche Bank AGReiterated RatingBuyN/AView Rating Details
10/23/2016BNP ParibasReiterated RatingBuyN/AView Rating Details
10/8/2016Shore CapitalReiterated RatingBuyN/AView Rating Details
10/1/2016Piper Jaffray CompaniesSet Price TargetHold$201.00N/AView Rating Details
6/3/2016Morgan StanleyReiterated RatingOverweightN/AView Rating Details
5/23/2016Bryan, Garnier & CoInitiated CoverageBuyN/AView Rating Details
3/30/2016Bank of America CorporationReiterated RatingBuyN/AView Rating Details
2/13/2016Northland SecuritiesReiterated RatingBuyN/AView Rating Details
2/8/2016Susquehanna Bancshares IncLower Price TargetPositive$280.00 -> $220.00N/AView Rating Details
1/18/2016Credit Suisse GroupUpgradeBuyN/AView Rating Details
10/21/2015William BlairReiterated RatingOutperform$276.00N/AView Rating Details
(Data available from 7/25/2015 forward)


Earnings History for Shire PLC (NASDAQ:SHPG)
Earnings by Quarter for Shire PLC (NASDAQ:SHPG)
Earnings History by Quarter for Shire PLC (NASDAQ SHPG)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2017Q1 17$3.22$3.63$3.57 billionViewListenView Earnings Details
2/16/2017Q416$3.24$3.37$3.78 billion$3.81 billionViewN/AView Earnings Details
11/1/2016Q316$3.21$3.17$3.57 billion$3.45 billionViewN/AView Earnings Details
8/2/2016Q216$3.03$3.38$2.28 billion$2.43 millionViewN/AView Earnings Details
4/29/2016Q1$3.05$3.19$1.71 billion$1.71 billionViewListenView Earnings Details
2/11/2016Q415$2.89$2.97$1.69 million$1.72 billionViewListenView Earnings Details
10/23/2015Q315$2.87$3.24$1.63 billion$1.58 billionViewListenView Earnings Details
7/23/2015Q215$2.81$2.63$1.59 billion$1.56 billionViewListenView Earnings Details
4/30/2015Q115$2.56$2.84$1.47 billion$1.49 billionViewN/AView Earnings Details
2/12/2015Q115$2.68$2.63$1.53 billion$1.58 billionViewN/AView Earnings Details
10/24/2014Q314$2.47$2.93$1.46 billion$1.55 billionViewListenView Earnings Details
7/18/2014Q214$2.45$2.67$1.45 billion$1.50 billionViewN/AView Earnings Details
5/1/2014Q114$2.22$2.36$1.38 billion$1.35 billionViewN/AView Earnings Details
2/13/2014Q413$2.02$2.26$1.28 billion$1.33 billionViewN/AView Earnings Details
10/24/2013Q213$1.65$1.77$1.23 billion$1.24 billionViewN/AView Earnings Details
7/25/2013$1.60$1.79$1.21 billion$1.28 billionViewN/AView Earnings Details
5/2/2013Q113$1.56$1.63$1.21 billion$1.16 billionViewN/AView Earnings Details
2/14/2013Q412$1.58$1.58$1.20 billion$1.20 billionViewN/AView Earnings Details
10/25/2012$1.47$1.36ViewN/AView Earnings Details
8/1/2012$1.52$1.68ViewN/AView Earnings Details
4/26/2012$0.52$1.24ViewN/AView Earnings Details
2/9/2012$0.48$0.44ViewN/AView Earnings Details
10/28/2011$1.31$1.28ViewN/AView Earnings Details
7/28/2011$1.24$1.33ViewN/AView Earnings Details
4/28/2011$1.18$1.23ViewN/AView Earnings Details
2/10/2011$1.04$1.03ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Shire PLC (NASDAQ:SHPG)
2017 EPS Consensus Estimate: $14.75
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174$3.22$3.36$3.31
Q2 20174$3.53$3.69$3.60
Q3 20174$3.59$3.89$3.77
Q4 20174$3.81$4.26$4.07
(Data provided by Zacks Investment Research)


Current Dividend Information for Shire PLC (NASDAQ:SHPG)
Most Recent Dividend:4/25/2017
Annual Dividend:$0.91
Dividend Yield:0.55%
Payout Ratio:122.97% (Trailing 12 Months of Earnings)
6.14% (Based on This Year's Estimates)
5.51% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Shire PLC (NASDAQ:SHPG)

Dividend History by Quarter for Shire PLC (NASDAQ SHPG)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Shire PLC (NASDAQ:SHPG)
No insider trades for this company have been tracked by


Headline Trends for Shire PLC (NASDAQ:SHPG)
Latest Headlines for Shire PLC (NASDAQ:SHPG)
DateHeadline logoShire PLC (SHPG) Given Average Recommendation of "Buy" by Brokerages - July 24 at 5:20 PM logoShire PLC (NASDAQ:SHPG) Expected to Earn FY2017 Earnings of $14.63 Per Share - July 20 at 9:53 AM logoExane Asset Management Buys Monsanto Co, Biogen Inc, Qiagen NV, Sells Citigroup Inc, W R Grace, ... - July 20 at 7:42 AM logoFY2018 EPS Estimates for Shire PLC (NASDAQ:SHPG) Decreased by Analyst - July 19 at 1:56 PM logoWilliam Blair Equities Analysts Lower Earnings Estimates for Shire PLC (SHPG) - July 19 at 9:57 AM logoMarinus Pharmaceuticals (MRNS) and Shire PLC (NASDAQ:SHPG) Critical Survey - July 18 at 10:19 PM logoQ2 2017 EPS Estimates for Shire PLC Decreased by SunTrust Banks (NASDAQ:SHPG) - July 18 at 9:35 AM logoShire Expands Broad Monoclonal Antibody Research Platform, Enters License Agreement for Novimmune Bi-specific ... - Nasdaq - July 18 at 8:08 AM logoShire plc (SHPG): Pressure Creates Buying Opportunity - BTIG - - July 18 at 8:08 AM logoShire Expands Broad Monoclonal Antibody Research Platform, Enters License Agreement for Novimmune Bi-specific Antibody - July 18 at 8:08 AM logoShire plc : Notice of Results - July 18 at 8:08 AM logoShire PLC (NASDAQ:SHPG) Given "Buy" Rating at BTIG Research - July 17 at 9:02 PM logoShire PLC (NASDAQ:SHPG) Cut to Sell at Zacks Investment Research - July 17 at 2:52 PM logoShire PLC (NASDAQ:SHPG) Receives Market Perform Rating from Sanford C. Bernstein - July 16 at 7:34 PM logoContrasting Shire PLC (NASDAQ:SHPG) and SciClone Pharmaceuticals (SCLN) - July 14 at 10:54 AM logo5 Pharma & Biotech Stocks That Could Be Big Winners in Q2 Earnings - July 13 at 9:29 AM logoShire PLC (NASDAQ:SHPG) Receives Buy Rating from Stifel Nicolaus - July 12 at 10:36 AM logo$3.75 Billion in Sales Expected for Shire PLC (SHPG) This Quarter - July 12 at 9:51 AM logoStifel Reiterates Buy on Shire plc (SHPG) Following Competitor Data Release - - July 12 at 7:59 AM logo$3.53 EPS Expected for Shire PLC (SHPG) This Quarter - July 10 at 6:18 PM logoShire Completes NDA Filing for Hemophilia Drug with FDA - Nasdaq - July 9 at 12:26 PM logoShire PLC (NASDAQ:SHPG) Upgraded by ValuEngine to "Buy" - July 8 at 2:52 PM logoShire submits iNDA to FDA for SHP654 for treatment of Hemophilia A - July 6 at 9:01 AM logoShire Submits Investigational NDA To FDA For Gene Therapy Candidate SHP654 - July 6 at 9:01 AM logoShire plc : Additional Listing - July 6 at 9:01 AM logoEquities Analysts Set Expectations for Shire PLC's FY2017 Earnings (NASDAQ:SHPG) - July 6 at 8:44 AM logoShire PLC (SHPG) Rating Increased to Hold at HSBC Holdings plc - July 6 at 7:46 AM logoShire submits investigational New Drug Application to FDA for Gene Therapy candidate SHP654 for treatment of Hemophilia A - July 6 at 7:38 AM logo3 Reasons Sizzling-Hot Bioverativ Stock Can Go Even Higher - July 5 at 10:39 AM logoShire plc : Total voting rights - July 4 at 7:20 AM logoShire plc : Director/PDMR Shareholding - July 4 at 7:20 AM logoShire PLC (NASDAQ:SHPG) PT Set at $222.00 by Cantor Fitzgerald - July 3 at 6:25 PM logoShire PLC (SHPG) Stock Rating Lowered by BidaskClub - July 1 at 3:42 PM logoShire PLC (SHPG) Given Consensus Rating of "Buy" by Analysts - June 27 at 2:39 PM logoBiocryst and Shire under pressure on FDA approval of Behring's HAE med - June 25 at 6:26 AM logoShire PLC (SHPG) Upgraded at BidaskClub - June 23 at 5:54 PM logoSHIRE TO PRESENT NEW DATA AT ISTH 2017 TO ADVANCE THE STANDARD OF CARE IN HEMOPHILIA - June 23 at 8:46 AM logoEMA accepts Shire's marketing application for recombinant therapy for inherited bleeding disorder; shares ahead 2% premarket - June 22 at 6:36 PM logoShire plc (SHPG) Granted Marketing Authorization from EMA for Veyvondi - June 22 at 6:36 PM logoShire wins FDA approval for new ADHD drug - June 22 at 6:35 PM logoShire Announces EMA Validation of Veyvondi Marketing Authorization Application for Treatment of Von Willebrand Disease - June 22 at 6:35 PM logoSupernus Pharma (SUPN) Announces Partner, Shire PLC (SHPG), Granted FDA Approval for Mydayis for ADHD - - June 22 at 1:34 PM logoShire plc (SHPG) Granted Marketing Authorization from EMA for Veyvondi - - June 22 at 1:34 PM logoCould Shire PLC (SHPG) Be a Great Stock for Value Investors? - Nasdaq - June 20 at 7:38 AM logoCould Shire PLC (SHPG) Be a Great Stock for Value Investors? - June 20 at 7:37 AM logoShire PLC (SHPG) Downgraded to "Strong Sell" at BidaskClub - June 16 at 8:08 PM logoShire PLC (SHPG) Research Coverage Started at Cantor Fitzgerald - June 16 at 10:06 AM logo$3.54 EPS Expected for Shire PLC (SHPG) This Quarter - June 14 at 6:24 PM logoShire Investors Have Overreacted To Lialda News - Seeking Alpha - June 14 at 8:07 AM logo10 High-Quality Foreign-Stock Bargains - June 14 at 8:07 AM



Shire PLC (SHPG) Chart for Tuesday, July, 25, 2017

This page was last updated on 7/25/2017 by Staff